Benzinga | Aug 5, 2021 03:13PM EDT

Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer

* The FDA has accepted Exelixis Inc's (NASDAQ:EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid cancer (DTC).

* The application under priority review covers patients 12 years and older who have progressed following prior therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).

* The agency action date is December 4, 2021.

* Price Action: EXEL shares are down 1.40% at $17.03 during the market session on the last check Thursday.

* Related content: Benzinga's Full FDA Calendar.